ArticleFrontiers in microbiology2011
Development of vaccines against burkholderia pseudomallei.
Article in Frontiers in microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Outer membrane vesicles in gram-negative bacteria and its correlation with pathogenesis.Frontiers in immunology · 2025Review
- LVS ΔmBio · 2024Article
- Efficacy of Treatment with the Antibiotic Novobiocin against Infection withAntibiotics (Basel, Switzerland) · 2022Article
- Enhanced serodiagnosis of melioidosis by indirect ELISA using the chimeric protein rGroEL-FLAG300 as an antigen.BMC infectious diseases · 2022Article
- Immunization and Immunotherapy Approaches againstVaccines · 2021Review
- Review
- Hijacking of the Host's Immune Surveillance Radars byFrontiers in immunology · 2021Review
- An increase in p62/NBR1 levels in melioidosis patients of Sri Lanka exhibit a characteristic of potential host biomarker.Journal of medical microbiology · 2020Article
- Immune responses in beta-thalassaemia: heme oxygenase 1 reduces cytokine production and bactericidal activity of human leucocytes.Scientific reports · 2020Observational
- Human Melioidosis.Clinical microbiology reviews · 2020Review
- Evaluation of Burkholderia mallei ΔtonB Δhcp1 (CLH001) as a live attenuated vaccine in murine models of glanders and melioidosis.PLoS neglected tropical diseases · 2019Article
- Modelling population dynamics and seasonal movement to assess and predict the burden of melioidosis.PLoS neglected tropical diseases · 2019Article
- Antibodies Are Major Drivers of Protection against Lethal Aerosol Infection with Highly PathogenicmSphere · 2019Article
- Recent Advances in the Synthesis of Glycoconjugates for Vaccine Development.Molecules (Basel, Switzerland) · 2018Review
- Melioidosis.Nature reviews. Disease primers · 2018Review
- Immune Control ofFrontiers in immunology · 2018Article
- DNA vaccination resurfaces in the struggle against melioidosis.Virulence · 2017Article
- Antibodies againstInfection and immunity · 2017Article
- Deciphering minimal antigenic epitopes associated with Burkholderia pseudomallei and Burkholderia mallei lipopolysaccharide O-antigens.Nature communications · 2017Article
- Host gene expression analysis in Sri Lankan melioidosis patients.PLoS neglected tropical diseases · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Burkholderia pseudomallei is a Gram-negative bacterium which is the causative agent of melioidosis, a disease which carries a high mortality and morbidity rate in endemic areas of South East Asia and Northern Australia. At present there is no available human vaccine that protects against B. pseudomallei, and with the current limitations of antibiotic treatment, the development of new preventative and therapeutic interventions is crucial. This review considers the multiple elements of melioidosis vaccine research including: (i) the immune responses required for protective immunity, (ii) animal models available for preclinical testing of potential candidates, (iii) the different experimental vaccine strategies which are being pursued, and (iv) the obstacles and opportunities for eventual registration of a licensed vaccine in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.